MARKET

SABS

SABS

SAB BIOTHERAPEUTICS INC
NASDAQ
3.800
-0.070
-1.81%
After Hours: 3.813 +0.013 +0.34% 19:14 06/26 EDT
OPEN
3.810
PREV CLOSE
3.870
HIGH
3.950
LOW
3.680
VOLUME
5.65M
TURNOVER
--
52 WEEK HIGH
6.60
52 WEEK LOW
1.670
MARKET CAP
290.56M
P/E (TTM)
-2.6551
1D
5D
1M
3M
1Y
5Y
1D
SAB BIOTHERAPEUTICS INC. <SABS.O>:  BARCLAYS INITIATES COVERAGE WITH OVERWEIGHT RATING AND TARGET PRICE $13
Reuters · 3d ago
U.S. RESEARCH ROUNDUP-Caseys General Stores, Micron Technology, SAP
Reuters · 3d ago
SAB Biotherapeutics Price Target Announced at $13.00/Share by Barclays
Dow Jones · 3d ago
Barclays Initiates Coverage On SAB Biotherapeutics with Overweight Rating, Announces Price Target of $13
Benzinga · 3d ago
SAB Biotherapeutics initiated with an Overweight at Barclays
TipRanks · 4d ago
Weekly Report: what happened at SABS last week (0615-0619)?
Weekly Report · 6d ago
SAB Biotherapeutics Shareholders Back Board and Auditor
TipRanks · 06/18 22:38
SAB Biotherapeutics shareholders elect four Class II directors at annual meeting
PUBT · 06/18 20:36
More
About SABS
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.

Webull offers SAB Biotherapeutics Inc stock information, including NASDAQ: SABS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SABS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SABS stock methods without spending real money on the virtual paper trading platform.